Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home (Part 1 of 2)
This article was originally published in PharmAsia News
Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players that have enjoyed success on their own turf will become a global threat.
You may also be interested in...
HYDERABAD, India - Shantha Biotechnics, the Sanofi-owned Indian vaccines company, has received prequalification by the World Health Organization for a range of vaccines, including the pentavalent Shan 5 vaccine brand that had been previously disqualified by the world agency following detection of impurities in some batches
Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.
Chinese Manufacturers Will Cut Into India's Vaccine Exports Unless Indian Firms Can Find New Approach - World Vaccine Congress Asia
SINGAPORE - China will overtake India as the world's largest producer of vaccines in the coming years unless Indian companies manage properly their current niche in export markets, speakers said at the World Vaccine Congress Asia 2011 held June 20-24 in Singapore